PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
23667771-16	2013	The use of prokinetics, such as erythromycin, may be interesting in the clinic in decreasing the need for insulin in diabetic patients.	Erythromycin	32-44	insulin	Homo sapiens	106-113	
23667771-1	2013	AIM: To study the possible interactions of metoclopramide, domperidone and erythromycin in streptozotocin-induced diabetic mice treated with insulin by various parameters.	Erythromycin	75-87	insulin	Homo sapiens	141-148	
23667771-17	2013	The dose of insulin may be safely decreased with erythromycin in chronic treatments.	Erythromycin	49-61	insulin	Homo sapiens	12-19	
23667771-10	2013	Erythromycin tended to decrease blood glucose level and increase serum insulin level after 1 wk of daily administration in diabetic mice.	Erythromycin	0-12	insulin	Homo sapiens	71-78	
23667771-11	2013	Erythromycin potentiated the effect of insulin on blood glucose level and serum insulin level whereas other prokinetic agents failed to do so after repeated dose administration in diabetic mice.	Erythromycin	0-12	insulin	Homo sapiens	39-46	
10819233-9	2000	Erythromycin infusion significantly increased plasma insulin and decreased glucose concentrations in Type II diabetic and control subjects and greatly potentiated glucose-induced insulin secretion in the latter (third study).	Erythromycin	0-12	insulin	Homo sapiens	53-60	
23667771-11	2013	Erythromycin potentiated the effect of insulin on blood glucose level and serum insulin level whereas other prokinetic agents failed to do so after repeated dose administration in diabetic mice.	Erythromycin	0-12	insulin	Homo sapiens	80-87	
15983224-14	2005	However, when erythromycin was added to GLP-1, insulin concentrations were similar to those in placebo experiments.	Erythromycin	14-26	insulin	Homo sapiens	47-54	
9203450-0	1997	Erythromycin derivative improves gastric emptying and insulin requirement in diabetic patients with gastroparesis.	Erythromycin	0-12	insulin	Homo sapiens	54-61	
9203450-5	1997	CONCLUSIONS: Preliminary results obtained from a small number of patients suggest that EM523L or erythromycin analogs, which have agonistic activity to motilin receptors as well as no antibacterial effect, may be useful to accelerate gastric emptying and improve insulin requirement patterns, thereby establishing more stable glycemic control.	Erythromycin	97-109	insulin	Homo sapiens	263-270